Physician profile
Robert M Bauer
NPI 1366432924
$3,775.62
in general payments reported to CMS, 2019-2025
29 companies · $1,814 in 2025
The $1,814 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $184 · 2021: $414 · 2022: $279 · 2023: $255 · 2024: $642 · 2025: $1,814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,970 · Travel and Lodging: $741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,969.85 |
| Travel and Lodging | $740.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,729.49 | 2022-2025 | Unity, Clareon, Voyager Dslt |
| Horizon Therapeutics Plc | $205.82 | 2021-2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $203.03 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $156.21 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $127.43 | 2019-2024 | |
| Amgen INC. | $125.42 | 2024-2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $110.02 | 2019-2021 | |
| Biotissue Holdings INC. | $106.07 | 2022-2024 | |
| Lensar, INC. | $95.48 | 2025 | Lensar Laser System |
| Abbvie INC. | $83.49 | 2019-2025 | |
| Glaukos Corporation | $83.34 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Bausch & Lomb Americas INC. | $82.70 | 2023-2024 | Vyzulta, Envista Mx60 Iol, Miebo |
| Tarsus Pharmaceuticals, INC. | $81.15 | 2024-2025 | Xdemvy |
| Rxsight INC | $61.68 | 2024-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Mallinckrodt Hospital Products INC. | $60.13 | 2025 | Acthar |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $57.83 | 2025 | Vevye, Iheezo |
| Allergan, INC. | $56.33 | 2019-2021 | |
| Optos, INC. | $48.49 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $43.43 | 2025 | Tecnis Simplicity |
| Ocular Therapeutix, INC. | $43.41 | 2021 | |
| Dompe US, INC. | $42.04 | 2025 | Oxervate |
| Supernus Pharmaceuticals, INC. | $39.04 | 2024 | Qelbree |
| Alimera Sciences, INC. | $35.36 | 2023-2024 | Iluvien, Yutiq |
| Ani Pharmaceuticals, INC. | $20.08 | 2025 | Yutiq |
| Sight Sciences, INC. | $19.97 | 2024 | Omni Surgical System |
| Akorn, INC. | $19.29 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.02 | 2021 | |
| Shire North American Group INC | $13.00 | 2019 | |
| Thea Pharma INC. | $12.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.